28. Off-balance sheet arrangements
Contractual obligations and commitments
On 31 December 2021, we had outstanding obligations for future purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than |
1 - 3 years |
3 - 5 years |
More than |
|---|---|---|---|---|---|
Purchase commitments |
369,937 |
212,065 |
105,947 |
46,426 |
5,499 |
On 31 December 2020, we had outstanding obligations for future purchase commitments, which become due as follows:
(thousands of €) |
Total |
Less than |
1 - 3 years |
3 - 5 years |
More than |
|---|---|---|---|---|---|
Purchase commitments |
347,873 |
271,922 |
73,009 |
2,870 |
72 |
In addition to the tables above, we have a contractual cost sharing obligation related to our collaboration agreement with Gilead for filgotinib. This amounted to €369.9 million on 31 December 2021 (€493.4 million at 31 December 2020), for which we have purchase commitments of €169.6 million at 31 December 2021 (€18.1 million at 31 December 2020) reflected in the tables above.